Literature DB >> 11328408

Glutathione S-transferase GSTM1 and GSTT1 genotypes in ovarian cancer: association with p53 expression and survival.

R E Howells1, T Holland, K K Dhar, C W Redman, P Hand, P R Hoban, P W Jones, A A Fryer, R C Strange.   

Abstract

The objective of this study was to determine whether the association between GSTM1 null/GSTTI null and survival in ovarian cancer is mediated by the influence of these genes on p53 expression. In 81 women with pure invasive ovarian cancer, GSTM1 null and GSTT1 null genotypes were identified using polymerase chain reaction and p53 expression was assessed using immunohistochemistry. The association of these factors with survival was examined using Cox's proportional hazards regression models. Performance status (P < 0.001), operative stage (P = 0.004), residual disease (P = 0.001), histologic subtype (P = 0.05), tumor grade (P = 0.007), and the combined GSTMI null/GSTTl null genotype (P = 0.023) were all individually associated with survival. p53 expression was not associated with survival (P = 0.45). In a multivariate analysis, the effects of GSTM1 null/GSTT1 null on survival were lost when residual disease and tumor grade were included. The effects of p53 expression on survival were unchanged when residual disease, tumor grade, operative stage, and performance score were included. GSTM1 null/GSTT1null did not influence the effects of p53 expression on survival and vice versa. The GSTM1 null/GSTT1 null genotype was associated with response to primary chemotherapy (P = 0.007) but p53 expression was not. We conclude that the association of GSTM1 null/GSTTl null with survival appears to be mediated through different mechanisms to p53 expression in ovarian cancer and in addition, may be a better predictor of outcome.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11328408     DOI: 10.1046/j.1525-1438.2001.011002107.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  12 in total

1.  Molecular characteristics of non-small cell lung cancer.

Authors:  M Nacht; T Dracheva; Y Gao; T Fujii; Y Chen; A Player; V Akmaev; B Cook; M Dufault; M Zhang; W Zhang; M Guo; J Curran; S Han; D Sidransky; K Buetow; S L Madden; J Jen
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

2.  Genetic polymorphism of GSTP1 and ERCC1 correlated with response to platinum-based chemotherapy in non-small cell lung cancer.

Authors:  Hongying Lv; Ting Han; Xiaoli Shi; Yasai Yao; Yongru Yao; Wensheng Qiu; Lu Yue; Jun Liang
Journal:  Med Oncol       Date:  2014-06-24       Impact factor: 3.064

Review 3.  Prognostic significance of several biomarkers in epithelial ovarian cancer: a meta-analysis of published studies.

Authors:  Linjuan Xu; Jing Cai; Qiang Yang; Hui Ding; Liying Wu; Tao Li; Zehua Wang
Journal:  J Cancer Res Clin Oncol       Date:  2013-04-18       Impact factor: 4.553

4.  Role of glutathione-S-transferase and codon 72 of P53 genotypes in epithelial ovarian cancer patients.

Authors:  Elaine Cristina Morari; Andre Bacellar Costa Lima; Natassia Elena Bufalo; Janaina Luisa Leite; Fabiana Granja; Laura Sterian Ward
Journal:  J Cancer Res Clin Oncol       Date:  2006-05-19       Impact factor: 4.553

5.  Identification of multiple DNA copy number alterations including frequent 8p11.22 amplification in conjunctival squamous cell carcinoma.

Authors:  Laura Asnaghi; Hind Alkatan; Alka Mahale; Maha Othman; Saeed Alwadani; Hailah Al-Hussain; Sabah Jastaneiah; Wayne Yu; Azza Maktabi; Deepak P Edward; Charles G Eberhart
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-12-09       Impact factor: 4.799

Review 6.  Pharmacogenomics: a tool for improving cancer chemotherapy.

Authors:  Mariano Monzó; Alfons Navarro; Gerardo Ferrer; Rosa Artells
Journal:  Clin Transl Oncol       Date:  2008-10       Impact factor: 3.405

7.  Associations between p53 overexpression and multiple measures of clinical outcome in high-risk, early stage or suboptimally-resected, advanced stage epithelial ovarian cancers A Gynecologic Oncology Group study.

Authors:  Kathleen M Darcy; William E Brady; John W McBroom; Jeffrey G Bell; Robert C Young; William P McGuire; R Ilona Linnoila; Denver Hendricks; Tomas Bonome; John H Farley
Journal:  Gynecol Oncol       Date:  2008-10-02       Impact factor: 5.482

8.  Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis.

Authors:  P de Graeff; A P G Crijns; S de Jong; M Boezen; W J Post; E G E de Vries; A G J van der Zee; G H de Bock
Journal:  Br J Cancer       Date:  2009-06-09       Impact factor: 7.640

9.  Early detection biomarkers for ovarian cancer.

Authors:  Sreeja Sarojini; Ayala Tamir; Heejin Lim; Shihong Li; Shifang Zhang; Andre Goy; Andrew Pecora; K Stephen Suh
Journal:  J Oncol       Date:  2012-12-23       Impact factor: 4.375

Review 10.  Cancer drugs, genetic variation and the glutathione-S-transferase gene family.

Authors:  Danyelle Townsend; Kenneth Tew
Journal:  Am J Pharmacogenomics       Date:  2003
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.